Publications

First-in-human clinical trial design of a first-in-class theranostic approach with a peptide-based radioligand targeting CAIX-expressing tumors

Debio 0123-101, a phase 1 trial of Debio 0123 in combination with carboplatin in advanced solid tumors: safety, pharmacokinetic, and…

Debio 0123 is a selective WEE1 inhibitor that effectively penetrates the brain and demonstrates anti-tumor activity in preclinical models of…

Pharmacokinetic-pharmacodynamic modelling of afabicin in vitro activity against Staphylococcus aureus

Debio 0123, A Selective WEE1 Inhibitor in Clinical Development for Patients with Solid Tumors

Safety assessment of DPI-4452, a cyclic peptide targeting Carbonic Anhydrase IX

Predicting response to naratuximab emtansine, an anti-CD37 antibody-drug conjugate (ADC), in combination with rituximab in diffuse Large B Cell Lymphoma…

Pharmacodynamic marker modulation of the selective WEE1 inhibitor Debio 0123 in patient biopsies from phase 1 clinical trial

Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression…